Caris Life Sciences Q2 revenue rises 45% on the back of molecular profiling services

Caris Life Sciences

05/08/2026 21:59

Overview
US molecular diagnostics firm's Q2 revenue rose 45% yr/yr, driven by molecular profiling services
Company narrowed net loss to $0.6 mln from $71.8 mln a year earlier
Caris raised 2026 revenue guidance to $1.03-$1.04 bln, up 27%-28% yr/yr

Outlook
Caris Life Sciences raises 2026 revenue guidance to $1.03-$1.04 bln
Company reaffirms 2026 clinical therapy selection volume growth of about 20%

Result Drivers
MOLECULAR PROFILING SERVICES - Co said 45% revenue growth was driven primarily by a 55% rise in molecular profiling services revenue, supported by higher clinical case volume and ASP improvements
CLINICAL CASE VOLUME - Clinical case volume rose 18% yr/yr to about 59,200, contributing to revenue growth
GROSS MARGIN IMPROVEMENT - Gross margin rose to 68%, up 500 bps from prior year, attributed to higher case volume and ASP improvements

Company press release: ID:nPnS7Qm2a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$263.71 mln
 
Q2 Net Loss
 
$637,000
 
Q2 Income From Operations
 
$26.93 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Caris Life Sciences, Inc. is $27.50, about 70.8% above its August 4 closing price of $16.10
The stock recently traded at 67 times the next 12-month earnings vs. a P/E of 88 three months ago

Reuters Recommended Reads
Aug 3 - GeneDx Q2 revenue beats analyst estimates
Aug 4 - Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage
Aug 5 - Charles River lifts profit forecast on improving biotech demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)